Zelgen Reports ZG006 Pivotal Interim Endpoint in SCLC

Zelgen disclosed that an independent monitoring committee found its randomized Chinese pivotal interim analysis of alveltamig, ZG006, met the prespecified primary efficacy endpoint in third-line or later advanced small-cell lung cancer. The filing does…





